COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.

ABSTRACT: The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received B-cell depleting anti-CD20 antibodies and chemotherapy for B-cell lymphomas. The control cohort consisted of age- and sex-matched patients without lymphoma who were hospitalized because of COVID-19. We performed detailed clinical analyses, in-depth cellular and molecular immune profiling, and comprehensive virological studies in 12 patients with available biospecimens. B-cell depleted lymphoma patients had more severe and protracted clinical course (median hospitalization 88 versus 17 d). All patients actively receiving immunochemotherapy (n = 5) required ICU support including long-term

SUBMITTER: Gaitzsch E 

PROVIDER: S-EPMC8240782 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature